ImpriMed, Inc.

In this episode of the Veterinary Cancer Pioneers Podcast, Dr. Rachel Venable interviews Dr. B Duncan X Lascelles, a distinguished professor, board-certified small animal surgeon, and Director of the Comparative Pain Research and Education Center (CPREC) at North Carolina State University. Dr. Lascelles highlights the critical role of pain management in veterinary oncology, emphasizing that: 1?? Pain is not just a byproduct of cancer, but it may actually contribute to cancer progression by suppressing immune function, releasing local pro-cancer factors, and promoting systemic nerve sensitization. 2?? Managing pain early and effectively may not only improve quality of life but also potentially extend survival in cancer patients. 3?? Pain management must be prioritized. This includes developing and using validated pain assessment tools and continuing to invest in research and education to guide evidence-based protocols. ?? Listen to the full interview here: https://lnkd.in/gHFfFUnm

Last month, our CEO, Dr. Sungwon Lim, attended the J.P. Morgan Healthcare Conference in Taipei, where he presented ImpriMed’s innovative live cancer cell platform and its influence on veterinary cancer care. He also shared how our approach is expanding into human healthcare and CRO services. ???? Joined by key industry leaders, investors, and experts from the global biotech and healthcare sectors, the discussion highlighted the critical role of AI in enabling data-driven decision-making in healthcare. #PrecisionMedicine #VeterinaryOncology #ArtificialIntelligence

In this episode of the Veterinary Cancer Pioneers Podcast, Dr. Rachel Venable speaks with Dr. Mark Mamula, Professor of Medicine (Rheumatology) at Yale School of Medicine, about his work on EGFR/HER2 immunotherapy for canine cancer. ?? ?? Here are some key takeaways from Dr. Mamula’s work: 1?? The vaccine, tested in osteosarcoma, hemangiosarcoma, and transitional cell carcinoma (TCC/bladder cancer), shows promising results, though tumor mutations remain a challenge. 2?? No major behavioral or systemic side effects have been observed, indicating a strong safety profile. 3?? Immunotherapy alone might not be sufficient but combination therapies may improve outcomes. A new trial is evaluating gilvetmab (PD-1 immunotherapy) with the EGFR/HER2 vaccine for hemangiosarcoma. ?? Listen to the full interview here: https://lnkd.in/gKJn6xrf

Exciting News from #ASCOGI25! We’re pleased to share that Abstract #738, led by Dr. Moonho Kim, MD, was presented at the American Society of Clinical Oncology (ASCO) GI 2025 in San Francisco, CA. Our machine learning models demonstrated the ability to predict treatment outcomes for FOLFIRINOX and Gemcitabine/Nab-Paclitaxel in patients with advanced or metastatic pancreatic cancer. This study explores how AI-driven predictive modeling can help enhance first-line therapy selection and enable more personalized treatment strategies. Building on these findings, we will be conducting a prospective multi-center randomization study and are looking for collaborators. If you are interested in partnering with us on this research, we would love to connect. Reach out to us at [email protected] to start the conversation! #PrecisionMedicine #PrecisionOncology #MachineLearning #Oncology #PancreaticCancer #ASCOGI

ImpriMed Featured on Dogster!?????? Our Director of Bioscience, Dr. Ilona Holcomb, joined Dr. Karyn Kanowski from Dogster for a discussion on how ImpriMed’s Personalized Prediction Profile (PPP) supports veterinary oncologists in making informed canine cancer treatment decisions. By analyzing live cancer cells with drug sensitivity testing and leveraging AI, ImpriMed's PPP helps identify the most effective chemotherapy options to improve patient outcomes. ?? To read more: https://lnkd.in/gSthD_mi

ImpriMed Provider Spotlight: Dr. Evan Sones, DVM, MS, DACVIM, Medical Director ar Animal Cancer Care Clinic ? Thank you Dr. Sones for supporting our continued efforts to use AI in transforming cancer care! We are delighted that you've chosen ImpriMed to help deliver the best care to your patients.??? ?? To learn more about how you can get started on ImpriMed services: https://bit.ly/4gNEuKg?

We’re thrilled to share that Dr. Sungwon Lim, Co-Founder and CEO of ImpriMed, has been recognized as one of the Top 50 Healthcare AI Entrepreneurs of 2025!??? ?? Since launching our Personalized Prediction Profile (PPP) in 2021, we’ve been committed to continuously refining our AI model—empowering veterinarians with data-driven insights to guide the best possible treatment plans for their patients. ?? Read more here: https://lnkd.in/gx5UJrSZ

We reached another significant milestone! ???? We recently processed our 8000th canine sample, a Personalized Prediction Profile (PPP) submission by Dr. Alexandra Rippoll from Veterinary Medical and Surgical Group. Since launching our AI-driven Personalized Prediction Profile (PPP) in 2021, we’ve been committed to continuously refining our model to ensure precision and reliability, empowering veterinarians to make data-driven treatment decisions for their patients. Thank you to all the veterinarians who have placed their trust in us! We look forward to continuing our journey together to advance veterinary care. ?? ?? Learn more about our Personalized Prediction Profile (PPP): https://lnkd.in/g4EzeCki

Happy Valentine’s Day from our beloved veterinary care teams and patients! ?? ?? We’re honored to work alongside veterinary cancer care teams who pour their hearts into caring for pets every day. Your dedication and compassion inspire us! ?? At ImpriMed, we’re here to support veterinarians with AI-driven insights, empowering them make the best treatment decisions for their patients’ cancer care. ?? Learn more about our services:?https://lnkd.in/gxTBGjUf Veterinary Cancer Care Harbour City Animal Hospital MedVet All Creatures Animal Hospital Atlantic Veterinary Internal Medicine & Oncology VETERINARY SPECIALISTS OF NORTH TEXAS, LLC

ImpriMed Provider Spotlight: Dr. Sue Ettinger, Veterinary Oncologist at Guardian Veterinary Specialists ?? ?? Thank you, Dr. Ettinger, for supporting our mission to transform cancer care through AI! We’re thrilled that you’ve chosen ImpriMed to help provide the best possible care for your patients. ?? ?? To learn more about how you can get started on ImpriMed services: https://bit.ly/4gNEuKg?